In short
Clinical trials are investigating Meloxicam in patients with axial spondyloarthritis. These studies look at how well it helps control disease activity and compare it with other treatments, including TNF blockers. The main focus is on adults who have already failed NSAID therapy in outpatient care.
Key points
- Clinical trials are studying Meloxicam in people with axial spondyloarthritis. The main trial is a Phase 3 study with 100 planned participants. It compares repeated high-dose NSAID therapy, including Meloxicam, with direct treatment using a TNF blocker. The key goal is to see how many patients reach low disease activity after 12 weeks. The study focuses on adults who have already failed NSAID therapy in outpatient care.
Trial overview
This clinical study is interventional, which means researchers give the study treatments and then measure the results. It is designed to compare repeated high-dose NSAID therapy with direct treatment using a TNF blocker in people with axial spondyloarthritis who have failed NSAID therapy in outpatient care.
Meloxicam is one of the NSAIDs listed in the study treatment group.
Who is being studied
The trial focuses on patients with axial spondyloarthritis, a disease that affects the spine and nearby joints. The brief summary says the study is for patients who have already failed NSAID therapy in outpatient care, so the target group has not done well enough with earlier NSAID treatment.
The study does not give more detailed entry rules in the source data, such as age limits or exact lab requirements.
Treatments being compared
The study includes several NSAIDs, such as diclofenac, indometacin, ibuprofen, acemetacin, etoricoxib, Meloxicam, celecoxib, and naproxen. These are compared with a TNF blocker called Remsima, which is listed in both infusion and injection forms.
In simple terms, the researchers are asking whether treatment with NSAIDs, including Meloxicam, can help patients reach a better disease state as well as or differently from a TNF blocker.
Trial phase and size
This study is in Phase 3. Phase 3 studies usually compare treatments in larger groups of patients and look closely at how well they work.
The planned enrollment is 100 participants. That means the study is expected to include about 100 patients in total.
What researchers measure
The main outcome is the proportion of patients on NSAID treatment versus TNF blocker treatment who reach low disease activity after 12 weeks. Low disease activity is measured using ASDAS, and the target is a score below 2.1.
This endpoint tells researchers how many patients improve enough to be considered less active in their disease after the treatment period.
What this means for patients
For patients, this trial is mainly about finding out whether Meloxicam, as part of the NSAID group, can help control axial spondyloarthritis better in people who have not responded well to earlier NSAID treatment. The study is not testing all possible uses of Meloxicam; it is focused on one disease group and one main treatment question.
The data available here show a direct comparison between treatment strategies, which can help researchers understand which approach may be more effective for lowering disease activity over 12 weeks.